Yidao Biotechnology develops recombinant protein, viral vector, peptide-polysaccharide conjugate, and mRNA vaccines to provide high-quality, low-cost immunization solutions for global health challenges. The company focuses on addressing the need for effective vaccines against various diseases, leveraging proprietary technology platforms to advance clinical research and product commercialization.
Funding
Funding not disclosed
Founders
Product
Problem
Globally, there is a need for high-quality, low-cost vaccines to address various health challenges and provide effective immunization solutions. Traditional vaccine development and manufacturing processes can be expensive and time-consuming.
Solution
Yidao Biotechnology develops innovative vaccines using recombinant protein, viral vector, peptide-polysaccharide conjugate, and mRNA technologies to combat global health challenges. The company focuses on creating high-quality, low-cost immunization solutions through proprietary technology platforms. Yidao Biotechnology has multiple vaccine candidates in its pipeline, including a recombinant zoster vaccine (CHO cells) and a 9-valent recombinant human papillomavirus vaccine (Pichia pastoris). These vaccines are undergoing clinical trials to assess their safety and efficacy.
Target Audience
The primary target audience includes individuals and populations in need of effective and affordable vaccines, as well as global health organizations and government agencies seeking to improve immunization coverage.
Features
- Recombinant protein vaccine development
- Viral vector vaccine development
- Peptide-polysaccharide conjugate vaccine development
- mRNA vaccine development
- Innovative vaccine adjuvant platform
- Clinical-stage recombinant zoster vaccine (CHO cells)
- Clinical-stage 9-valent recombinant human papillomavirus vaccine (Pichia pastoris)